Joosten et al. suggested that the monoclonal antibody lebrikizumab, which targets interleukin-13 (IL-13), has proven to be effective in reducing skin problems and symptoms in people suffering from moderate-to-severe atopic dermatitis during clinical trials [63]. Here, IL13 is linked to atopic eczema.